• Eli Lilly and Company has committed to roll out Veeva Vault CRM across its global operations, adopting Veeva’s agentic, AI-enabled commercial platform as its core customer relationship system.
• This global win with a leading pharmaceutical group underlines growing acceptance of Veeva’s Vault CRM Suite as the technology backbone for AI-driven commercial models in life sciences.
• We’ll now examine how Eli Lilly’s global Vault CRM commitment shapes Veeva’s investment narrative, especially its AI-enabled commercial cloud ambitions.

Capitalize on the AI infrastructure supercycle with our selection of the 57 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Veeva Systems Investment Narrative Recap

To own Veeva, you need to believe pharma will keep standardizing on its cloud as a core system of record, and that AI agents embedded in those workflows will become essential rather than optional. Eli Lilly’s global Vault CRM rollout directly supports that thesis and bolsters the short term catalyst around AI enabled commercial adoption, while also highlighting the key risk of customer concentration and the pressure to keep delivering proven, high impact AI capabilities at scale.

Among recent developments, the launches of Vault AI and Falcon, Veeva’s agentic labor platform, look most relevant here, since Lilly is standardizing on an AI enabled Vault CRM. Together with prior global CRM wins at Merck KGaA and Teva, this announcement connects those AI product releases to real world deployments and keeps execution risk squarely focused on whether Veeva can convert its broader AI roadmap into sustained adoption across large pharma accounts.

Yet against this positive backdrop, there is a concentration risk in top pharma accounts that investors should be aware of if...

Veeva Systems' narrative projects $4.7 billion revenue and $1.4 billion earnings by 2029.

Uncover how Veeva Systems' forecasts yield a $245.48 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Before Eli Lilly’s move, the most optimistic analysts were already modeling revenue of about US$5.0 billion and earnings of roughly US$1.6 billion by 2029, a view that looks more aggressive when you set it against slower AI adoption risks and shows how differently you and other investors might read this new CRM win.

Explore 12 other fair value estimates on Veeva Systems - why the stock might be worth as much as 35% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Veeva Systems research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Veeva Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veeva Systems' overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Uncover the next big thing with 19 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.